Similar results were obtained for patients with low (<1424) MII-2 levels compared with those with high (⩾1424) levels median PFS was 12.6 
  8.9 months (HR = 1.95, 95% CI 1.35-2.82, 
   = 0.0004) and median OS was 32.4 
  14.6 months, respectively (HR = 2.42, 95% CI 1.64-3.57, 
   < 0.0001). Patients with low (<6068) MII-3 levels had a longer median PFS and OS than those with high (⩾6068) levels 12.6 
  8.9 months (HR = 1.91, 95% CI 1.33-2.76, 
   = 0.005) and 30.9 
  15.0 months (HR = 2.10, 95% CI 1.43-3.09, 
   = 0.0002), respectively. Following adjustment for clinical covariates, multivariate analysis confirmed all MII indexes as independent prognostic factors for predicting PFS and OS.
 
  All MII indexes appear to be useful as prognostic markers.
 
  ClinicalTrials.gov identifier NCT01878422 (registration date 07/06/2013) https//clinicaltrials.gov/ct2/show/NCT01878422.
 ClinicalTrials.gov identifier NCT01878422 (registration date 07/06/2013) https//clinicaltrials.gov/ct2/show/NCT01878422.
  Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death. In cases with metastasis, the combination of 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based chemotherapy regimens are considered the standard of care. However, the optimal sequence of these regimens is unclear.
 
  This retrospective study initially evaluated 186 patients with locally advanced/metastatic pancreatic cancer at three Italian institutions between February 2013 and October 2019. All patients had progressed after receiving gemcitabine-based first-line chemotherapy and were subsequently offered second-line FOLFIRINOX, FOLFOX-6, or FOLFIRI treatment.  https://www.selleckchem.com/products/dn02.html  This study evaluated progression-free survival (PFS), overall survival from the start of second-line treatment (OS2), overall survival from the start of first-line treatment (OS1), and safety outcomes.
 
  A total of 77 patients received ⩾4 cycles of second-line chemotherapy and were considered eligible 15 patients received FOLFIRINOX, 32 patients received FOLFOX-6, and 30 patients received FOLFIRI. The FOLFIRINOX group had median PFS of 26.29 weeks and median OS2 of 47.86 weeks, while the FOLFIRI group had median PFS of 10.57 weeks and median OS2 of 25.00 weeks (
   = 0.038). No significant differences were observed between the FOLFIRINOX and FOLFOX-6 groups in terms of PFS (26.29 weeks 
  23.07 weeks) or OS2 (47.86 weeks 
  42.00 weeks). The most common grade 3-4 toxicities were anemia, neutropenia, and thrombocytopenia, which occurred more frequently in the FOLFIRINOX and FOLFOX-6 groups.
 
  Relative to the FOLFIRI regimen, the FOLFIRINOX regimen had a favorable toxicity profile and better survival outcomes. No significant differences were observed relative to the FOLFOX-6 regimen.
 Relative to the FOLFIRI regimen, the FOLFIRINOX regimen had a favorable toxicity profile and better survival outcomes. No significant differences were observed relative to the FOLFOX-6 regimen.
  To examine the effects of gastric bypass surgery on health-related quality of life (HRQoL) in obese patients with type 2 diabetes, and to investigate their experiences of life adjustments using quantitative and qualitative methods.
 
  Thirteen patients with type 2 diabetes and obesity, (body mass index, BMI > 30kg/m
  ), participating in a randomized clinical trial, completed this sub-study. HRQoL was evaluated before, and at 6months and 2years after gastric bypass surgery, using the RAND- 36-item health survey. At 2years, interviews for in-depth analysis of HRQoL changes were performed.
 
  Significant improvement was observed from baseline to 6months for 2 of the eight health concepts, general health, and emotional well-being. At 2years, improvements were also seen in physical functioning, energy/fatigue, as well as sustained improvements in general health and emotional well-being. Multiple regression analyses showed mostly non-significant associations between the magnitude of decrease in weight, BMI, and ltrials.gov/ct2/show/NCT02729246?term=bariglykos&draw=2&rank=1.
  Brazil is one of top 10 countries with the highest number of people with diabetes mellitus (DM), affecting 16.8 million peoples. It is estimated that 7.7 million people (20-79years) in the country have not yet been diagnosed, representing an under-diagnosis rate of 46.0%. Herein we aimed to screen people for high blood glucose or risk for developing type 2 DM (T2DM) through community pharmacies in Brazil.
 
  A cross-sectional study was carried out in November 2018, involving 977 pharmacists from 345 municipalities in Brazil. The study evaluated people between 20 and 79years old without a previous diagnosis of DM. Glycemia was considered high when its value was ≥ 100mg/dL fasting and ≥ 140mg/dL in a casual feeding state. The FINDRISC (Finnish Diabetes Risk Score) was used to estimate the risk for developing T2DM. The prevalence of high blood glucose was estimated and the associated factors were obtained using Poisson's multivariate analysis with robust variance.
 
  During the national screening campaign, 17,58eening and education actions aimed at this undiagnosed population in a continent-size country such as Brazil.
 This is the largest screening study that evaluated the frequency of high blood glucose and its associated factors in a population without a previous diagnosis ever performed in community pharmacies in Brazil. These results may help to improve public health policies and reinforce the role of pharmacists in screening and education actions aimed at this undiagnosed population in a continent-size country such as Brazil.
  The influence of pre-pregnancy body mass index (BMI) and gestational weight gain (GWG) on perinatal outcomes of women with polycystic ovary syndrome (PCOS) remains unclear. Therefore, we explored how the above indicators influence pregnancy outcomes in women with PCOS.
 
  A retrospective study was conducted involving the baseline characteristics, laboratory data, and pregnancy outcomes of 722 pregnant women with PCOS. Subjects were grouped in a way to find out risks in their pregnancy outcomes. Multivariable logistic regression analysis was performed to investigate how BMI and GWG were associated with perinatal outcomes.
 
  Among women with PCOS, underweight increased the risk of small for gestational age (SGA) (OR 12.35, 95% CI 3.56-42.82), but reduced the risk of large for gestational age (LGA). Overweight but not obese women were more susceptible to developing preeclampsia (PE) than women with normal weight. In PCOS women with BMI < 25kg/m
  before pregnancy, inadequate GWG was a protective factor for gestational hypertension (GH) and postpartum hemorrhage (PPH), excessive GWG exhibited a positive correlation with LGA.